We recently identified a compensatory survival role for protein kinase D1 (PKD1) in protecting dopaminergic neurons from oxidative insult. To investigate the molecular mechanism of Prkd1 gene expression, we cloned the 5'-flanking region (1620-bp) of the mouse Prkd1 gene. Deletion analyses revealed that the -250/+113 promoter region contains full promoter activity in MN9D dopaminergic neuronal cells. In silico analysis of the Prkd1 promoter uncovered binding sites for key redox transcription factors including Sp1 and NF-κB. Over-expression of Sp1, Sp3, and NF-κB-p65 proteins stimulated Prkd1 promoter activity. Binding of Sp3 and NF-κB-p65 to the Prkd1 promoter was confirmed using chromatin immunoprecipitation. Treatment with the Sp inhibitor mithramycin A significantly attenuated Prkd1 promoter activity and PKD1 mRNA and protein expression. Further mechanistic studies revealed that inhibition of histone deacetylation and DNA methylation up-regulated PKD1 mRNA expression. Importantly, negative modulation of PKD1 signaling by pharmacological inhibition or shRNA knockdown increased dopaminergic neuronal sensitivity to oxidative damage in a human mesencephalic neuronal cell model. Collectively, our findings demonstrate that Sp1, Sp3, and NF-κB-p65 can transactivate the mouse Prkd1 promoter and that epigenetic mechanisms, such as DNA methylation and histone modification, are key regulatory events controlling the expression of pro-survival kinase PKD1 in dopaminergic neuronal cells. Previously, we demonstrated that protein kinase D1 (PKD1) plays a survival role during the early stage of oxidative stress in dopaminergic neuronal cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839478PMC
http://dx.doi.org/10.1111/jnc.13261DOI Listing

Publication Analysis

Top Keywords

prkd1 promoter
20
dopaminergic neuronal
16
prkd1 gene
12
kinase pkd1
12
promoter activity
12
neuronal cells
12
sp3 nf-κb-p65
12
prkd1
8
promoter
8
survival role
8

Similar Publications

Pharmacogenetics of novel glucose-lowering drugs.

Diabetologia

June 2021

Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.

Article Synopsis
  • This work reviews studies on how genetic variants influence the effectiveness of new glucose-lowering drugs like DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors.
  • It highlights that specific gene variants, particularly in the GLP-1 receptor gene (GLP1R), are linked to different responses to these treatments, but many findings lack sufficient replication or statistical support.
  • The study suggests that using genome-wide association studies could provide better insights, and emphasizes the need to identify subgroups of type 2 diabetes for more effective personalized treatment strategies.
View Article and Find Full Text PDF

Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail.

Cell Death Differ

January 2020

Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong, 510006, China.

Article Synopsis
  • The study explores how BRD4, a protein involved in regulating genes, impacts cancer cell movement and processes like epithelial-mesenchymal transition (EMT) in breast cancer.
  • Inhibiting BRD4 leads to reduced cell migration, invasion, and tumor growth, particularly through lowering levels of the EMT transcription factor Snail by affecting its stability and expression.
  • The research suggests that BRD4's regulation of Snail involves interactions with Protein Kinase D1 and Gli1, and both BRD4 and Snail are associated with more aggressive forms of breast cancer, especially those lacking certain hormone receptors.
View Article and Find Full Text PDF

Down regulation of Protein Kinase D1 (PrKD1), a novel serine threonine kinase, in prostate, gastric, breast and colon cancers in humans leads to disease progression. While the down regulation of PrKD1 by DNA methylation in gastric cancer and by nuclear beta-catenin in colon cancer has been shown, the regulatory mechanisms in other cancers are unknown. Because we had demonstrated that PrKD1 is the only known kinase to phosphorylate threonine 120 (T120) of beta-catenin in prostate cancer resulting in increased nuclear beta-catenin, we explored the role of beta-catenin in gene regulation of .

View Article and Find Full Text PDF

Deletion of protein kinase D1 in osteoprogenitor cells results in decreased osteogenesis in vitro and reduced bone mineral density in vivo.

Mol Cell Endocrinol

February 2018

Institute for Regenerative and Reparative Medicine, Augusta University, 30912, United States; Department of Orthopaedic Surgery, Augusta University, 30912, United States; Department of Neuroscience and Regenerative Medicine, Augusta University, 30912, United States.

Protein kinase D1 (PRKD1) is thought to play a role in a number of cellular functions, including proliferation and differentiation. We hypothesized that PRKD1 in bone marrow-derived mesenchymal stem cells (BMMSC) could modulate osteogenesis. In BMMSCs from floxed PRKD1 mice, PRKD1 ablation with adenovirus-mediated Cre-recombinase expression inhibited BMMSC differentiation in vitro.

View Article and Find Full Text PDF

The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.

Sci Rep

September 2016

Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL 32224, USA.

Increased expression of PRKD1 and its gene product protein kinase D1 (PKD1) are linked to oncogenic signaling in pancreatic ductal adenocarcinoma, but a direct functional relationship to oncogenic KRas has not been established so far. We here describe the PRKD1 gene promoter as a target for oncogenic KRas signaling. We demonstrate that KRas-induced activation of the canonical NF-κB pathway is one mechanism of how PRKD1 expression is increased and identify the binding sites for NF-κB in the PRKD1 promoter.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!